[HTML][HTML] European expert panel consensus on the clinical management of BRAFV600E-mutant metastatic colorectal cancer
E Martinelli, D Arnold, A Cervantes, S Stintzing… - Cancer Treatment …, 2023 - Elsevier
Metastatic colorectal cancer (mCRC) is a heterogenous disease caused by various genetic
alterations. The BRAF V600E mutation occurs in approximately 8–12% of patients and is …
alterations. The BRAF V600E mutation occurs in approximately 8–12% of patients and is …
WNT5A: a double-edged sword in colorectal cancer progression
The Wnt signaling pathway is known to play a crucial role in cancer, and WNT5A is a
member of this pathway that binds to the Frizzled (FZD) and Receptor Tyrosine Kinase-Like …
member of this pathway that binds to the Frizzled (FZD) and Receptor Tyrosine Kinase-Like …
Atypical (non‐V600E) BRAF mutations in metastatic colorectal cancer in population and real‐world cohorts
E Osterlund, A Ristimäki, MJ Mäkinen… - … Journal of Cancer, 2024 - Wiley Online Library
Abstract BRAF‐V600E mutation (mt) is a strong negative prognostic and predictive
biomarker in metastatic colorectal cancer (mCRC). Non‐V600Emt, designated atypical …
biomarker in metastatic colorectal cancer (mCRC). Non‐V600Emt, designated atypical …
BRAFV600E in colorectal cancer reduces sensitivity to oxidative stress and promotes site-specific metastasis by stimulating glutathione synthesis
J Laoukili, S van Schelven, E Küçükköse, A Verheem… - Cell reports, 2022 - cell.com
The presence of BRAF V600E in colorectal cancer (CRC) is associated with a higher chance
of distant metastasis. Oxidative stress in disseminated tumor cells limits metastatic capacity …
of distant metastasis. Oxidative stress in disseminated tumor cells limits metastatic capacity …
Safety and efficacy of irinotecan, oxaliplatin, and capecitabine (XELOXIRI) regimen with or without targeted drugs in patients with metastatic colorectal cancer: a …
X Liu, K Ou, X Ma, L Gao, Q Wang, H Zhang, L Yang - BMC cancer, 2022 - Springer
Background Five-fluorouracil, folinic acid, oxaliplatin and irinotecan (FOLFOXIRI) regimen is
used as the first-line treatment for metastatic colorectal cancer (mCRC). The use of …
used as the first-line treatment for metastatic colorectal cancer (mCRC). The use of …
The therapeutic impact of programmed death–1 in the treatment of Colorectal Cancer
PS Sangani, S Yazdani, G Khalili-Tanha… - … -Research and Practice, 2024 - Elsevier
Colorectal cancer (CRC) is the most common type of newly diagnosed cancer. Metastatic
spread and multifactorial chemoresistance have limited the benefits of current therapies …
spread and multifactorial chemoresistance have limited the benefits of current therapies …
A perspective on emerging therapies in metastatic colorectal cancer: Focusing on molecular medicine and drug resistance
AE Kusumaningrum, S Makaba, E Ali… - Cell Biochemistry …, 2024 - Wiley Online Library
The majority of cancer cases are colorectal cancer, which is also the second largest cause of
cancer‐related deaths worldwide. Metastasis is the leading cause of death for patients with …
cancer‐related deaths worldwide. Metastasis is the leading cause of death for patients with …
Prognostic and Predictive Factors in Metastatic Colorectal Cancer
E Österlund - 2024 - diva-portal.org
Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 2024. 67
pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-2049-6. The outcome for …
pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-513-2049-6. The outcome for …